A double blind randomized controlled trial to assess safety and efficacy of Cap. IP in COVID-19 positive patients with mild to moderate severity for early recovery, in restoring respiratory health and in improvement in innate immunity

AMAI Charitable Trust Pune0 个研究点目标入组 72 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Age > 18 years
•2.All sexes
•3.Case definitions for inclusion in the study will include mild to moderately severe cases as defined in the Guidance on appropriate treatment of suspect/confirmed case of COVI19 issued by Ministry of Health and Family Welfare, Govt of India on 07 Apr 2020.
•Mild: Cases presenting with fever and/or upper respiratory tract illness (Influenza like Illness, ILI); Moderate: Pneumonia with no signs of severe disease (Respiratory Rate 15 to 30/minute, SpO2 90%-94%). OR
•4.Laboratory confirmed SARS CoV-2 infection within last 10 days or SARS CoV-2 test result pending with a high clinical suspicion as defined by: Cough of more than 10 days duration OR
•5.Bilateral pulmonary infiltrates on chest X Ray / CT scan or new hypoxaemia defined as SpO2 <94% on room air, where no alternative explanation for respiratory symptoms can be given

•1.Pregnant or lactating women
•2.Symptoms of acute respiratory tract infection for more than seven days
•3.More than 48 hours have elapsed between meeting inclusion criteria and enrolment
•4.Subject is also a participant of any other clinical trial
•5.Serious / long-standing co-morbid conditions

发起方

AMAI Charitable Trust Pune